The regulatory decision was supported by data from the phase 1/2 LUMMICAR STUDY 1 trial (NCT03975907), which showed that at a median follow-up of 37.7 months (range, 14.8-44.2), evaluable patients treated with the <A href="https://cancerfax.com/revolutionizing-multiple-myeloma-treatment-through-car-t-cell-therapy-in-china/" target="_blank" rel="noopener">BCMA-targeted CAR T-cell therapy</A> (n = 14) achieved an overall response rate (ORR) of 100% and a complete response (CR)/stringent CR (sCR) rate of 78.6%.2 Notably, all patients with a CR/sCR had <A href="https://cancerfax.com/understanding-relations-between-mrd-and-car-t-cell-therapy/" target="_blank" rel="noopener">minimal residual disease</A>.</P> <P>“In the realm of traditional treatments, the prognosis for patients with relapsed or refractory multiple myeloma remains notably grim, given the lack of available therapeutic alternatives,” said Wenming Chen, MD, PhD, who led LUMMICAR STUDY 1 and is the director of the Hematology Department at China’s Beijing Chao-Yang Hospital of Capital Medical University. “These people have significant unmet clinical requirements, demanding the rapid adoption of effective, safe, and convenient therapeutic options. The approval of zevor-cel not only broadens the range of options available to clinical practitioners, but also gives <A href="https://cancerfax.com/new-hope-for-patients-with-locally-advanced-gastric-cancer/" data-wpil-monitor-id="5714">patients new hope</A>.